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1. Introduction 
Recently, we described an “enzyme-immunoassay” 
for human chorionic gonadotrophin (HCG *), using the 
enzyme horse radish peroxidase (HRP) as a label for 
the antigen instead of radioactive iodine, as used in 
radioimmunoassay [I] . Independently, Engvall et 
al. developed similar assay systems with alkaline 
phosphatase-labelled antigen [2, 31 or antibody [4]. 
We have now applied the enzyme-immunoassay 
principle to the determination of haptens * *. We used 
oestradiol and oestriol, coupled through succinyl 
bridges to HRP, and antibodies against these steroid 
hormones. The resulting assay systems are more or less 
analogous to the radioimmunoassays for steroid hor- 
mones [S] that have been developed after the initial 
demonstration that steroid hormones can act as haptens 
[6,71. 
2. Materials and methods 
2.1. Reagents 
Oestradiol- 17fl-hemisuccinate and oestriol- 16cq 17/3- 
dihemisuccinate were prepared by heating the oestrogens 
with excess succinic anhydride in pyridine, followed by 
hydrolysis of the 3-ester with dilute sulphuric acid and 
by repeated crystallisation from methanol. HRP, grade 
* Abbreviations used are: HCG: human chorionic gonado- 
trophin; HRP: horse radish peroxidase; E: oestrogen; El : 
oestrone; E 2 : oestradiol; Es: oestriol; BSA: bovine serum 
albumin. 
** Dutch patent application 7016396, filed 10th November 
1970. 
IV, R.Z. 0.6, was purchased from Miles-Seravac; BSA, 
Cohn fraction V, from Armour; sec. butylchloroformate 
and tri-n-butylamine from Fluka; S-aminosalicylic acid 
from EGA-Chemie. Various oestrogen sulphates and 
glucuronides were bought from Sigma. Lactalbumin 
was from De Meyerij, Veghel, The Netherlands. Dasp 
anti-rabbit (sheep antibodies against rabbit y-globulin, 
covalently linked to cellulose) is an Organon product. 
2.2. Preparation of oestrogen-protein conjugates 
E-BSA and E-HRP were prepared by a mixed an- 
hydride reaction, using sec. butylchloroformate. E- 
BSA was prepared essentially according to Erlanger et 
al. [8] , using a molar ratio E/BSA of 60. The number 
of E-residues per BSA molecule in the conjugates was 
estimated, both spectrophotometrically and by amino 
group determination with trinitrobenzene sulphonic 
acid [9], to be about 25 for E, -BSA and 32 for E3 - 
BSA. E-HRP conjugates were prepared using E/HRP 
ratios ranging from 5 to 40 (see Results). After the 
reaction they were passed over a Sephadex G-50 column, 
dialyzed and lyophilized, before subjecting them to 
further purification procedures (see Results). 
2.3. Preparation of antisera against E-BSA 
Rabbits received 3 x 1.25 mg immunogen subcuta- 
neously in complete Freund’s adjuvant, with 1Cday 
intervals, followed by an intravenous injection of 1.25 
mg immunogen in physiological saline. The rabbits 
were bled one week after the booster injection. If 
necessary, the animals received a second series of in- 
jections. 
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2.4. Enzyme-immunoassay procedures 
The double antibody solid phase method was used, 
employing Dasp anti-rabbit (sheep antibodies against 
rabbit y-globulin, covalently linked to cellulose) [ 10, 
1 l] . Incubation times and buffer were the same as in 
the Dasp enzyme-immunoassay for HCG [ 1 ] , except 
for the phosphate concentration of the buffer, which 
was increased to 0.1 M in order to avoid non-specific 
adsorption of E-HRP conjugates to the immunosorbent. 
2.5. Peroxidase assay 
HRP-activity was determined with 5aminosalicylic 
acid as oxygen-acceptor, as described earlier [l] . 
3. Results 
E-HRP conjugates were prepared while using molar 
E/HRP ratios ranging from 5 to 40. Fig. 1 shows the 
relation between E/HRP ratio and “immune reactivity”, 
defined as the percentage of the enzyme activity that 
can be bound by excess antibody against the corre- 
sponding steroid, for Ez -HRP and E3 -HRP. Since 
virtually no enzyme activity is lost during the coupling 
reaction, the yield of each conjugate before purification 
equals its immune reactivity. 
An Ez -HRP and an Es -HRP, both prepared with 
an E/HRP ratio of 20, were subjected to various purifi- 
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Fig. 1. Effect of E/HRP ratio (molar) during coupling on the 
immune reactivity of the unpurified E-HRP conjugates. 
(x--x--x)Ez-HRP; (o----o----o)Es-HRP. 
Table 1 
Purification of E-HRP conjugates by various methods. 
Ez -HRP E3-HRP 
--- 
Purification Immune Yield * Immune Yield * 
step reactivity (%) reactivity (%) 
(%) (70) 
--__ ___________ 
Non-purified 28 28 20 20 
Sephadex 
G-75 
48 
BioGel P-60 41 6 27 8 
Density gra- 
** 0.2 ** 
dient ultra- 
95 
64 5 ** ** centrifug tion 56 0.8 
* Yield is expressed as: 
enzyme activity product 
Immune reactivity product X initial enzyme activity 
** The Es-HRP ultracentrifuge fractions were pooled in two 
portions with different immune reactivity. 
The data apply to the pooled fractions with approsimately 
the highest immune reactivity. 
cation procedures. Iso-electric focusing and chromato- 
graphy on Sephadex LH-20 gave no fractions with in- 
creased immune reactivity. Table 1 shows the results of 
gel filtration on Sephadex G-75 and Biogel P-60, and of 
centrifugation on a linear 20-60% sucrose gradient at 
283,000 g for 40 hr. Since centrifugation gave the prod- 
ucts with the highest immune reactivity, the following 
experiments were performed with conjugates, purified 
by that method. 
Fig. 2 and 3 show the displacement of E-HRP con- 
jugates from their binding to antibodies by El, E, and 
E3. Fig. 2 shows the curves obtained with an anti-E3 
serum combined with an Ez -HRP and an E3 -HRP, 
fig. 3 shows the curves for the same conjugates and an 
anti-E* serum. We obtained similar results with various 
other antisera, although no antiserum showed as large 
a difference in reaction with Ez -HRP and E,-HRP as 
the one shown in fig. 3. With appropriate combinations 
of conjugate and antiserum, nanogram amounts of 
hapten could be detected. 
In order to evaluate the specificity of the assay 
systems, we tested various compounds, including 
oestrogen sulphates and glucuronides and non-oestro- 
genie steroids, with two different conjugate-antiserum 
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Fig. 2. Oestrogen assay systems: An E3-HRP (A) and an Ez-HRP (B), with anti-E3 serum 405 in dilutions of l/1400 and l/1200, 
respectively. (*--*--*)El ; (x- -x- -x)Ez; (~---&--n)E3. F= activity in supernatant wiit&dded hapten. Fo = activity in 
supernatant without added hapten. T= total enzyme activity. This amount of enzyme gives an AM of about 0.400 in the enzyme 
assay. 
combinations. The results are shown in table 2. Com- 
pounds showing lack of parallelism with the arbitrary 
standard oestrone are not strictly comparable with the 
other compounds. Therefore, they are marked in the 
table. 
4. Discussion 
A high quality of E-HRP conjugates is essential 
for the sensitivity of the resulting oestrogen enzyme- 
immunoassays. The immune reactivity is the only cri- 
terion we have used for the selection of the conjugates. 
Possibly, more sensitive assay systems can be developed 
if the conjugates requiring the smallest amount of anti- 
serum to bind for example 5% of the enzyme activity 
or the conjugates giving the steepest antiserum dilution 
curves are selected. 
The systems in figs. 2 and 3 are not strictly compa- 
rable because of the different antiserum dilutions used 
and the differing properties of E, -HRP and E3 -HRP 
conjugates. It appears, however, that more sensitive 
assay systems arise when Es -HRP is combined with 
an anti-E3 serum, and vice versa, than in homologous 
systems. This “mismatch” does not seem to affect the 
specificity of the systems. Cross-reaction between 
oestrogensis as high as could be expected from experi- 
ence with radioimmunoassays. Cross-reaction with non- 
oestrogen steroids is very low. 
The highly effective displacement obtained by E- 
hemisuccinates, as compared to the unmodified 
oestrogens (table 2), suggests that the antibodies are 
directed against both the oestrogen molecule and the 
succinyl bridge or parts of it. The finding that E, - 17- 
monoacetate and Ez -17-monopropionate displace 
3 H-E2 more efficiently from E2 - 17-succinyl-BSA 
antibodies than E2 itself [ 121, supports this assumption. 
This affinity for succinyl bridges may affect the sensi- 
tivity of our test system, in which the enzyme-labelled 
hapten contains succinyl bridges, and the haptens to be 
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Fig. 3. Oestrogen assay systems: An Ea-HRP (A) and an Ea-HRP 
respectively. For explanation of the symbols see legend to fig. 2. 
determined do not. The same effect may be expected 
in radioimmunoassays employing 1251-labelled E-suc- 
cinyl-BSA [13, 141, thus reducing the theoretical sen- 
sitivity gain from the higher specific activity. 
Oestrogens conjugated with sulphate or glucuronide 
at site 3 do not react in our systems, whereas 16” or 
17glucuronide oestrogens do, in many cases even as 
well as the unconjugated oestrogen (table 2). This 
might be expected, since Midgley reported that struc- 
tural differences at the end distal to conjugation have 
the greatest influence on the cross-reaction, while al- 
terations near the site of conjugation have little effect 
[ 141. Our Ez -HRP/anti E3 system, which crossreacts 
completely with E3 - 16- and E3 ~ 17glucuronide, is 
potentially applicable to E determination in pregnancy 
urine, where most of the E occurs as 16- or 17-conju- 
gated Ea. The application of a radioimmunoassay using 
anti-E, for E determination in pregnancy urine has 
been described [ 151. 
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(B), with anti-E* serum 408 in dilutions of l/700 and l/1000, 
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